缩写名/全名 |
FRONT MED-PRC
Frontiers of Medicine |
||||||||||||||||
ISSN号 | 2095-0217 | ||||||||||||||||
研究方向 | ONCOLOGYMEDICINE, RESEARCH & EXPERIMENTAL&-MEDICINE, RESEARCH & EXPERIMENTAL | ||||||||||||||||
影响因子 | 2015:1.863, 2016:1.634, 2017:2.027, 2018:1.847, 2019:3.421, | ||||||||||||||||
出版国家 | PEOPLES R CHINA | ||||||||||||||||
出版周期 | |||||||||||||||||
年文章数 | 70 | ||||||||||||||||
出版年份 | 0 | ||||||||||||||||
是否OA | No | ||||||||||||||||
审稿周期(仅供参考) | |||||||||||||||||
录用比例 | |||||||||||||||||
投稿链接 | https://mc.manuscriptcentral.com/fmd | ||||||||||||||||
投稿官网 | http://www.springer.com/medicine/journal/11684 | ||||||||||||||||
h-index | 28 | ||||||||||||||||
CiteScore |
|
||||||||||||||||
PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=2095-0217%5BISSN%5D | ||||||||||||||||
中科院SCI期刊分区 ( 2018年新版本) |
|
||||||||||||||||
中科院SCI期刊分区 ( 2020年新版本) |
|
中国学者近期发表的论文 | |
1. | Prospects of immunotherapy for cancer Author: Zhinan Chen Journal: Frontiers of Medicine, 2019, Vol.13, 1-2, DOI:10.1007/s11684-019-0691-y DOI |
2. | New incompatible pair of TCM: Epimedii Folium combined with Psoraleae Fructus induces idiosyncratic hepatotoxicity under immunological stress conditions Author: Yuan Gao, Zhilei Wang, Jinfa Tang, Xiaoyi Liu, Wei Shi, Nan Qin, Xiaoyan Wang, Yu Pang, Ruisheng Li, Yaming Zhang, Jiabo Wang, Ming Niu, Zhaofang Bai, Xiaohe Xiao Journal: Frontiers of Medicine, 2019, Vol., , DOI:10.1007/s11684-019-0690-z DOI |
3. | Urotensin II receptor antagonist reduces hepatic resistance and portal pressure through enhanced eNOS-dependent HSC vasodilatation in CCl<Subscript>4</Subscript>-induced cirrhotic rats Author: Ruoxi Zhang, Jing Chen, Diangang Liu, Yu Wang Journal: Frontiers of Medicine, 2019, Vol., , DOI:10.1007/s11684-019-0689-5 DOI |
4. | Immunotherapy-based combination strategies for treatment of gastrointestinal cancers: current status and future prospects Author: Chenfei Zhou, Jun Zhang Journal: Frontiers of Medicine, 2019, Vol.13, 12-23, DOI:10.1007/s11684-019-0685-9 DOI |
5. | Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy Author: Zhao Zhang, Jun Jiang, Xiaodong Wu, Mengyao Zhang, Dan Luo, Renyu Zhang, Shiyou Li, Youwen He, Huijie Bian, Zhinan Chen Journal: Frontiers of Medicine, 2019, Vol.13, 57-68, DOI:10.1007/s11684-019-0683-y DOI |
6. | Growth suppression of colorectal cancer expressing S492R EGFR by monoclonal antibody CH12 Author: Qiongna Dong, Bizhi Shi, Min Zhou, Huiping Gao, Xiaoying Luo, Zonghai Li, Hua Jiang Journal: Frontiers of Medicine, 2019, Vol.13, 83-93, DOI:10.1007/s11684-019-0682-z DOI |
7. | Presence of multiple abnormal immunologic markers is an independent prognostic factor of diffuse large B-cell lymphoma Author: Yiwen Cao, Zhenhua Liu, Wen Wu, Ying Qian, Qin Shi, Rong Shen, Binshen Ouyang, Pengpeng Xu, Shu Cheng, Jin Ye, Yiming Lu, Chaofu Wang, Chengde Yang, Li Wang, Weili Zhao Journal: Frontiers of Medicine, 2019, Vol.13, 94-103, DOI:10.1007/s11684-019-0680-1 DOI |
8. | Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy Author: Min Zhang, Jingwen Yang, Wenjing Hua, Zhong Li, Zenghui Xu, Qijun Qian Journal: Frontiers of Medicine, 2019, Vol.13, 32-44, DOI:10.1007/s11684-018-0678-0 DOI |
9. | High-affinity T cell receptors redirect cytokine-activated T cells (CAT) to kill cancer cells Author: Synat Kang, Yanyan Li, Yifeng Bao, Yi Li Journal: Frontiers of Medicine, 2019, Vol.13, 69-82, DOI:10.1007/s11684-018-0677-1 DOI |
10. | PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives Author: Yumeng Wang, Guiling Li Journal: Frontiers of Medicine, 2019, Vol., , DOI:10.1007/s11684-018-0674-4 DOI |
|